In one of the largest tumor-agnostic studies, BRAF/MEK inhibition with D/T was shown to have a median PFS of 11.4 months, ORR of 38%, and median duration of response of 25.1 months [18]. The gene discussed is MAP2K7; the disease is neoplasm.